Boceprevir: A novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 3, 2012, Pages 179-188

  Kwo, Paul Y ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Boceprevir; Direct acting antiviral; Hepatitis C; Interferon; Resistance; Ribavirin

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; KANAMYCIN KINASE; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RNA; SERINE PROTEINASE; VIRUS RNA;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; COMPARATIVE STUDY; DRUG WITHDRAWAL; DYSGEUSIA; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IN VITRO STUDY; LIVER FIBROSIS; MONOTHERAPY; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN STRUCTURE; RELAPSE; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; VIRUS REPLICATION; VIRUS RESISTANCE; VOMITING;

EID: 84860520910     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11436317     Document Type: Review

References (29)

1. Alter M.J. (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436–2441.
2. Bartenschlager R. (2002) Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 1: 911–916.
3. Bartenschlager R. Lohmann V. (2000) Replication of hepatitis C virus. J Gen Virol 81: 1631–1648.
4. Conjeevaram H.S. Fried M.W. Jeffers L.J. Terrault N.A. Wiley-Lucas T.E. Afdhal N. et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470–477.
5. Davis G.L. Alter M.J. El-Serag H. Poynard T. Jennings L.W. (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: 513–521.
6. Diago M. Shiffman M.L. Bronowicki J.P. Zeuzem S. Rodriguez-Torres M. Pappas S.C. et al. (2010) Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 51: 1897–1903.
7. El-Serag H.B. Rudolph K.L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557–2576.
8. Ferenci P. Laferl H. Scherzer T.M. Maieron A. Hofer H. Stauber R. et al. (2010) Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterology 138: 503–512.
9. Flint M. Mullen S. Deatly A.M. Chen W. Miller L.Z. Ralston R. et al. (2009) Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother 53: 401–411.
10. Gane E.J. Roberts S.K. Stedman C.A. Angus P.W. Ritchie B. Elston R. et al. (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376: 1467–1475.
11. Hoofnagle J.H. Seeff L.B. (2006) Peginterferon and ribavirin for chronic hepatitis C [see comment]. N Engl J Med 355: 2444–2451.
12. Kwo P.Y. Lawitz E.J. McCone J. Schiff E.R. Vierling J.M. Pound D. et al. (2010) Efficacy of boceprevir, an NS 3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376: 705–716.
13. Lauer G. Walker B. (2001 a) Hepatitis C virus infection. N Engl J Med 345: 41–52.
14. Lauer G.M. Walker B.D. (2001 b) Hepatitis C virus infection. N Engl J Med 345: 41–52.
15. Lohmann V. Körner F. Koch J.O. Herian U. Theilmann L. Bartenschlager R. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110–113.
16. Malcolm B.A. Liu R. Lahser F. Agrawal S. Belanger B. Butkiewicz N. et al. (2006) SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS 3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50: 1013–1020.
17. McHutchison J.G. Bacon B.R. (2005) Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 11 (10): S286–S295; quiz S307–S311.
18. Muir A.J. Bornstein J.D. Killenberg P.G. and Atlantic Coast Hepatitis Treatment Group (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites [see comment]. N Engl J Med 350: 2265–2271 [erratum in N Engl J Med 2004 351: 1268].
19. National Institutes of Health (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10–12, 2002). Gastroenterology 123: 2082–2099.
20. Poordad F. Bronowicki J.P. Gordon S.C. Zeuzem S. Jacobson I.M. Sulkowski M.S. et al. (2011 a) IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (Boc) combination therapy. J Hepatol 54 (Suppl. 1): S6–S6.
21. Poordad F. McCone J. Jr. Bacon B.R. Bruno S. Manns M.P. Sulkowski M.S. et al. (2011 b) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206.
22. Poynard T. McHutchison J. Davis G.L. Esteban-Mur R. Goodman Z. Bedossa P. et al. (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32: 1131–1137.
23. Rodriguez-Torres M. Jeffers L.J. Sheikh M.Y. Rossaro L. Ankoma-Sey V. Hamzeh F.M. et al. (2009) Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 360: 257–267.
24. Sarrazin C. Rouzier R. Wagner F. Forestier N. Larrey D. Gupta S.K. et al. (2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132: 1270–1278.
25. Schiff E. Poordad F.F. Jacobson I.M. Flamm S.L. Bacon B.R. Lawitz E.J. et al. (2008) Role of interferon response during RE-Treatment of null responders with boceprevir combination therapy: results of phase II trial. Gastroenterology 134: A755.
26. Shiffman M.L. Suter F. Bacon B.R. Nelson D. Harley H. Sola R. et al. (2007) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357: 124–134.
27. Sulkowski M.S. Shiffman M.L. Afdhal N.H. Reddy K.R. McCone J. Lee W.M. et al. (2010) Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 139: 1602–1611.
28. Thompson A.J. Muir A.J. Sulkowski M.S. Ge D. Fellay J. Shianna K.V. et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120–129.
29. Vierling J. Flamm S.L. Gordon S.C. Lawitz E. Bronowicki J.P. Davis M. et al. (2011) Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE study. Hepatology 54 (Suppl. 1): 796A.